0000899243-21-040858.txt : 20211020 0000899243-21-040858.hdr.sgml : 20211020 20211020185933 ACCESSION NUMBER: 0000899243-21-040858 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211013 FILED AS OF DATE: 20211020 DATE AS OF CHANGE: 20211020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WIINBERG ULF CENTRAL INDEX KEY: 0001187314 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 211335231 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-10-13 0 0001840229 MiNK Therapeutics, Inc. INKT 0001187314 WIINBERG ULF 149 FIFTH AVENUE, SUITE 500 NEW YORK NY 10010 1 0 0 0 Common Stock 278300 D Stock Option (Right to Buy) 0.02 2028-11-19 Common Stock 27830 D Stock Option (Right to Buy) 0.01 2030-01-30 Common Stock 111320 D Stock Option (Right to Buy) 3.03 2031-02-11 Common Stock 20872 D Represents an option to purchase shares of the common stock, which vests in three equal annual installments beginning on November 19, 2019. Represents an option to purchase shares of our common stock, which vested as to 33% of the underlying shares on January 30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment. Represents an option to purchase shares of the common stock, which vests fully on February 11, 2022. Exhibit List: Exhibit 24 - Power of Attorney /s/ Christine Klaskin, attorney-in-fact 2021-10-20 EX-24 2 attachment1.htm EX-24 DOCUMENT

                             LIMITED POWER OF ATTORNEY

    The undersigned hereby constitutes and appoints Jennifer S. Buell and
Christine M. Klaskin, and each of them individually, with full power of
substitution, as the undersigned's true and lawful attorney-in-fact to:

    (1)   prepare, execute in the undersigned's name and on the undersigned's
          behalf, and submit to the U.S. Securities and Exchange Commission (the
          "SEC") a Form ID, including amendments thereto, and any other
          documents necessary or appropriate to obtain codes and passwords
          enabling the undersigned to make electronic filings with the SEC of
          reports required by Section 16(a) of the Securities Exchange Act of
          1934, as amended, or any rule or regulation of the SEC;

    (2)   execute for and on behalf of the undersigned, in the undersigned's
          capacity as officer and/or director of MiNK Therapeutics, Inc. (the
          "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance
          with Section 16(a) of the Securities Exchange Act of 1934, as amended,
          and the rules thereunder;

    (3)   do and perform any and all acts for and on behalf of the undersigned
          that may be necessary or desirable to complete and execute any such
          Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any
          amendment or amendments thereto, and timely file such form with the
          SEC and any stock exchange or similar authority; and

    (4)   take any other action of any type whatsoever in connection with the
          foregoing that, in the opinion of each such attorney-in-fact, may be
          of benefit to, in the best interest of, or legally required by, the
          undersigned, it being understood that the documents executed by each
          such attorney-in-fact on behalf of the undersigned pursuant to this
          Power of Attorney shall be in such form and shall contain such terms
          and conditions as each such attorney-in-fact may approve in each such
          attorney-in-fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that each such attorney-in-fact, or each
such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to
be done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that each foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D
or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to each foregoing attorney-in-fact.

                    [Remainder of page intentionally left blank]


    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 20th day of October, 2021.


                                          /s/ Ulf Wiinberg
                                        -----------------------------
                                        Name: Ulf Wiinberg


                    [Signature Page to Limited Power of Attorney